This document is a published patent application from the USPTO concerning a novel method for metabolic selection using the serine biosynthesis pathway. The application, titled 'Metabolic Selection via the Serine Biosynthesis Pathway,' describes an isolated mammalian cell engineered to have reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). It also outlines methods for preparing these cells and utilizing them for the production of recombinant proteins.

As this is a patent application, it does not impose direct regulatory obligations on companies. However, it signifies potential future intellectual property developments in biotechnology and pharmaceutical manufacturing. Companies involved in recombinant protein production or cell-based therapies should be aware of this filing as it may impact future research, development, and commercialization strategies in this area.